A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This is a Phase I/II study designed to evaluate the safety, tolerability, PK and PD of subcutaneous MIL116, an anti-APRIL monoclonal antibody, in healthy participants and patients with IgA Nephropathy.
Epistemonikos ID: 76c5bd6e21d3e21ff368f42826c610f25e658f19
First added on: Jan 30, 2026